Please assess the completion status of the following clinical trial:

Trial Title: TrasGEX™: Phase 1 Study in Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Signed written informed consent granted prior to initiation of any study-specific procedures;~2. Male or female patients of ≥18 years of age;~3. ERBB2 (HER-2) gene amplification or ERBB2 overexpression~4. Histologically or cytologically confirmed cancer, either locally advanced or metastatic;~5. No anti-tumor therapy of proven benefit available at study enrollment;~6. Life expectancy of \>=3 months;~7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) \<=2;~8. Male or female patients of child-producing potential must agree to use contraceptive measures or oral contraception during the study and for 28 days after the last dose of TrasGEX™;~9. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose of TrasGEX™;~and~Main Exclusion Criteria:~1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks of the first dose of TrasGEX™;~2. Major surgery within four weeks of the first dose of TrasGEX™;~3. Newly diagnosed brain metastases, metastases that have been documented to be stable for \<3 months, or metastases for which systemic corticosteroids are required;~4. History of allergic reactions attributed to compounds of similar chemical or biologic composition as TrasGEX™;~5. History of myocardial infarction within 12 months of the administration of the first dose of TrasGEX™;~6. History of congestive heart failure defined as Class II to IV per New York Heart Association classification within 12 months of the administration of the first dose of TrasGEX™;~7. Left ventricular ejection fraction \<50%;~8. Previous malignancy other than the current diagnosis within 5 years of the first dose of TrasGEX™;~9. Pregnancy or lactation; and~10. Concurrent uncontrolled significant illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TrasGEX (Type: EXPERIMENTAL): A total of 37 patients with advanced HER2-positive carcinomas and progressive disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).